Skip to main content
January 12

January 12, 2022
Bad Homburg, Germany

Commerzbank and ODDO BHF German Investment Seminar

January 10

January 10, 2022 - 02:15 pm - 00:00 am
Bad Homburg, Germany

40th Annual J.P. Morgan Healthcare Conference - Virtual

January 10 – 11, 2022

Q3-2021-Results

The following charts describe the shareholder structure of Fresenius SE & Co. KGaA (as of December 31, 2025). The Else Kröner-Fresenius-Stiftung is the largest shareholder of Fresenius SE & Co. KGaA, with 27% of the shares. In addition, we received several notifications pursuant to the German Securities Trading Act (WpHG) as listed below.      

Shareholder structure by investors

.

Shareholder structure institutional investors by region

Full text of the publications in accordance with Section 40 German Securities Trading Act (WpHG) (until January 2, 2018, in accordance with Section 26 WpHG) :

Share Price

Data is delayed by 15 minutes.

Share Price Information

Related Links

Interactive Tool

Here you will find the key figures for the Fresenius Group. Additional key financial figures are available at our interactive analysis tool, which can be used to process or analyze the figures in graphical form.

Key Credit Figures Fresenius Group (IFRS)

2024 2023 2022

Net debt/EBITDA1,2,3
at LTM average FX rates for both net debt and EBITDA

3.0 3.8 3.8

 

     

Debt (€m)

13,577 15,830 14,708

Net debt (€m)1 

11,295 13,268 13,316

 

     

Cash Conversion Rate1

1.0 1.0 0.9

EBITDA/Financial result1,3 

8.3 8.4 13.8

  • 1 The previous year’s figures were adjusted due to divestments and the deconsolidation of Fresenius Medical Care
    2 Proforma closed acquisitions/divestitures, including lease liabilities, including Fresenius Medical Care dividend​​​​​​​
    3 Before special items

Explanatory video: Nutrition therapy

The Fresenius SE & Co. KGaA Commercial Paper Program enables Fresenius to issue short-term notes of up to €1.5 bn on the money market. The issuances are made through the European Commercial Paper Program (ECP). 

Commercial Paper Program

Issuer Fresenius SE & Co. KGaA, Fresenius Finance Ireland plc.

Program amount

€ 1,500,000,000

Arranger

Commerzbank

Dealer

Barclays, Commerzbank, Crédit Agricole, DZ BANK AG, Landesbank Baden-Württemberg, Landesbank Hessen-Thüringen, ING Bank N.V.

Issuing and paying agent

Commerzbank

Term

up to 1 year less 1 day

Commercial Paper Program as Download

Fresenius Kabi is investing about €35 million to modernize the company’s production facility in Louviers, France. Two sterilization units and two production lines for Freeflex® infusion bags will be housed in a 3,300-square-meter (35,500-square-foot) building being constructed on the site and will replace the existing production facilities. In this way, the company will continue to ensure the availability of these important products into the future. The modernization is scheduled for completion before the end of 2023. Fresenius Kabi employs some 370 people at the Louviers plant and has a total of about 1,500 employees in France.

Fresenius Kabi is investing about €35 million to modernize the company’s production facility in Louviers, France. Two sterilization units and two production lines for Freeflex® infusion bags will be housed in a 3,300-square-meter (35,500-square-foot) building being constructed on the site and will replace the existing production facilities. In this way, the company will continue to ensure the availability of these important products into the future. The modernization is scheduled for completion before the end of 2023. Fresenius Kabi employs some 370 people at the Louviers plant and has a total of about 1,500 employees in France.

Subscribe to